Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare advantage population

International Journal of COPD

Volumn 10, Issue , 2015, Pages 565-576

  Moll, Keran ^a   Sun, Shawn X ^b   Ellis, Jeffrey J ^a   Howe, Andrew ^a   Amin, Alpesh ^c  

^a Formerly of Comprehensive Health Insights Inc   (United States)

^b Health Economics and Outcomes Research Forest Laboratories LLC an affiliate of Actavis Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

COPD; Exacerbations; Health care utilization; Medicare; Roflumilast

Indexed keywords

ROFLUMILAST; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MIDDLE AGED; OUTCOME ASSESSMENT; OUTPATIENT CARE; POPULATION RESEARCH; RISK REDUCTION; VERY ELDERLY; AGE; AMBULATORY CARE; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMIC MODEL; ECONOMICS; HEALTH CARE PLANNING; HOSPITAL COST; HOSPITALIZATION; MULTIVARIATE ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDY; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; UTILIZATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMBULATORY CARE; AMINOPYRIDINES; BENZAMIDES; CHI-SQUARE DISTRIBUTION; COST-BENEFIT ANALYSIS; CYCLOPROPANES; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HEALTH RESOURCES; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; LINEAR MODELS; MALE; MEDICARE PART C; MIDDLE AGED; MODELS, ECONOMIC; MULTIVARIATE ANALYSIS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84929391109     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S79025     Document Type: Article

References (32)

1. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med. 2002;96:700–708.
2. Dalal AA, Christensen L, Liu F, et al. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis. 2010;5:341–349.
3. Albertson TE, Schivo M, Zeki AA, et al. The pharmacological approach to the elderly COPD patient. Drugs Aging. 2013;30:479–502.
4. Bhatt NY, Wood KL. What defines abnormal lung function in older adults with chronic obstructive pulmonary disease? Drugs Aging. 2008;25:717–728.
5. Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:627–643.
6. Incalzi RA, Scarlata S, Pennazza G, et al. Chronic obstructive pulmonary disease in the elderly. Eur J Intern Med. 2014;25:320–328.
7. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE group. Respir Res. 2010;11:122.
8. Wedzicha JA. The heterogeneity of chronic obstructive pulmonary disease. Thorax. 2000;55:631–632.
9. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014. Available from: http://www.goldcopd.org. Accessed January 15, 2014.
10. Daliresp [package insert]. St Louis, MO, USA: Forest Pharmaceuticals, Inc; 2013.
11. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374:685–694.
12. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trials. Lancet. 2009;374:695–703.
13. Lindenauer PK, Pekow PS, Lahti MC, et al. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010;303:2359–2367.
14. Mapel DW, Dutro MP, Marton JP, et al. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data. BMC Health Serv Res. 2011;11:43.
15. Harvey R, Drzayich-Jankus D, Mosley D; United Healthcare. Random assignment of proxy event dates to unexposed individuals in observational studies: an automated technique using SAS®. Available from: http://www.mwsug.org/proceedings/2012/PH/MWSUG-2012-PH02.pdf. Accessed February 11, 2015.
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.
17. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258–1267.
18. Rabe KF, Bateman ED, O’Donnell D, et al. Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 2005;366:563–571.
19. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:154–161.
20. Wedzicha JA, Rabe KF, Martinez FJ, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest. 2013;143:1302–1311.
21. Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.
22. Berger ML, Mamdani M, Atkins D, et al. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report – Part I. Value Health. 2009;12:1044–1052.
23. Sun SX, Marynchenko M, Banerjee R, et al. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. J Med Econ. 2011;14:805–815.
24. Hertel N, Kotchie RW, Samyshkin Y, et al. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis. 2012;7:183–199.
25. Samyshkin Y, Kotchie RW, Mörk AC, et al. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Eur J Health Econ. 2014;15:69–82.
26. Rutten-van Mölken MP, van Nooten FE, Lindemann M, et al. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics. 2007;25:695–711.
27. Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130–139.
28. Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:549–555.
29. Wan Y, Shorr A, Sun S, et al. Impact of roflumilast on exacerbations among patients with chronic obstructive pulmonary disease (COPD) in the real world. Chest. 2013;144:745A.
30. Fu A, Sun S, Huang X, et al. 30-Day readmission rate associated with roflumilast treatment among patients hospitalized for COPD. Chest. 2013;144:744A.
31. Jain R, Cai Q, Sun SX, et al. Impact of roflumilast treatment on health care utilizations and costs among COPD patients in a managed care population. J Manag Care Pharm. 2014;20:S36.
32. Calverley PM, Martinez FJ, Fabbri LM, et al. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis. 2012;7:375–382.